PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

TOS statement on oral GLP-1s

2025-04-22
(Press-News.org) ROCKVILLE, MD-Advances in evidence-based obesity medications and treatment options are critical for the millions of individuals living with the chronic disease. The Obesity Society is encouraged by the development of new options that are effective, safe, and convenient for consumers. 

Last week, results released for the ACHIEVE-1 Phase 3 clinical trial suggest that a new medication, Orforglipron, an oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist, taken once daily led to an average weight loss of 7.9% in individuals with diabetes and impaired glycemic control.  Researchers noted that participant weight loss had not yet plateaued hinting that additional weight reduction from the drug could be realized. 

“What is exciting about the study and results for Orforglipron is that the safety and tolerability of an oral GLP-1 medication was consistent with injectable therapies.  Individuals with diabetes improved their hemoglobin A1C by an average of 1.3% to 1.6%, with more than 65% achieving a level equal or below 6.5% from a baseline of 8%,” stated Marc-Andre Cornier, MD FTOS, president of The Obesity Society (TOS). “This oral medication may be easy for individuals to take consistently and could prove to be more accessible than weekly injections.” 

The positive news about the results of Orforglipron came on the tail of the announcement that a different Phase 3 clinical trial for another oral daily drug, danuglipron, was being halted. An asymptomatic participant in one of the dose-optimization studies experienced a potential drug-induced liver injury that resolved with cessation of the medication. After careful review of the case and other data, the company made the decision to stop the development of the drug. 

“Clinical trials allow researchers to measure the safety and health outcomes associated with obesity medications. In this case, the study brought to light safety concerns and the trial was halted,” noted Cornier. “Obesity research is an important factor in determining best approaches to care and treatment, we need to ensure that as a nation we invest in and support studies that advance medicine.”

###  

The Obesity Society (TOS) is the leading organization of scientists and health professionals devoted to understanding and reversing the epidemic of obesity and its adverse health, economic and societal effects. Combining the perspective of researchers, clinicians, policymakers and patients, TOS promotes innovative research, education and evidence-based clinical care to improve the health and well-being of all people with obesity. For more information, visit www.obesity.org. 

END



ELSE PRESS RELEASES FROM THIS DATE:

Pulmonary fibrosis has no cure. Could a cancer drug hold the answer?

2025-04-22
Researchers at Tulane University have identified a potential new way to treat idiopathic pulmonary fibrosis (IPF), a deadly and currently incurable lung disease that affects more than 3 million people worldwide. IPF is rapidly progressive and causes scarring in the lungs, making it difficult to breathe. Approximately 50% of patients die within three years of diagnosis, and current treatments can only slow the disease — not stop or reverse it.  In a study published in the Journal ...

Trial explores drug-free approach to treat ADHD symptoms in children exposed to alcohol before birth

2025-04-22
Researchers at UCLA Health are launching the first clinical trial to test whether a wearable device that delivers gentle nerve stimulation during sleep could ease ADHD symptoms in children with prenatal alcohol exposure. Children exposed to alcohol in the womb have a heightened risk of developing ADHD-like symptoms including hyperactivity, impulsivity and executive function deficits such as difficulty paying attention, remembering, and organizing their behavior. Prenatal alcohol exposure affects about 5% of children in the U.S. with the majority developing these symptoms. ...

New research points out a promising strategy for treating metastatic medulloblastoma

2025-04-22
Researchers at Baylor College of Medicine, Texas Children’s Hospital, the Hospital for Sick Children in Toronto and collaborating institutions reveal in Nature Cell Biology a strategy that helps medulloblastoma, the most prevalent malignant brain tumor in children, spread and grow on the leptomeninges, the membranes surrounding the brain and spinal cord. They discovered a novel line of communication between metastatic medulloblastoma and leptomeningeal fibroblasts that mediates recruitment and reprogramming of the latter to support tumor growth. The findings suggest that disrupting this communication offers a potential opportunity to treat this devastating ...

Light fields with extraordinary structure: plasmonic skyrmion bags

2025-04-22
“Our results add another chapter to the emerging field of skyrmion research,” proclaims Prof. Harald Giessen, head of the Fourth Physics Institute at the University of Stuttgart, whose group achieved this breakthrough. The team demonstrated the existence of “skyrmion bags” of light on the surface of a metal layer. A better understanding of physical phenomena Skyrmions are a mathematical description of vortex-like structures that help researchers better understand fundamental physical relationships. In recent years, this theoretical ...

DNA origami guides new possibilities in the fight against pancreatic cancer

2025-04-22
CHAMPAIGN, Ill. — One of the challenges of fighting pancreatic cancer is finding ways to penetrate the organ’s dense tissue to define the margins between malignant and normal tissue. A new study uses DNA origami structures to selectively deliver fluorescent imaging agents to pancreatic cancer cells without affecting normal cells. The study, led by University of Illinois Urbana-Champaign mechanical science and engineering professor Bumsoo Han and professor Jong Hyun Choi at Purdue University, found that specially engineered DNA origami structures carrying imaging dye packets can specifically target human KRAS mutant ...

PREPSOIL launches assessment tool for soil living lab and lighthouse initiatives

2025-04-22
This tool is specifically designed to assess how well your initiative aligns with the EU Mission: A Soil Deal for Europe (Mission Soil) criteria for Soil Living Labs and Lighthouses, as further defined by the PREPSOIL taxonomy.  Should your initiative meet the necessary criteria, you will be invited to participate in a more detailed assessment developed by the SOILL-Startup project. This next phase will provide an opportunity to join a network of 100 Soil Living Labs and ...

Lebanon crisis driving parents to seek unregulated “shadow” education, study shows

2025-04-22
Political and social crisis in Lebanon has forced parents to seek unregulated “shadow” education for their children, a new study shows. The government’s ongoing neglect of public education is intensifying social inequality, experts have warned. The current sectarian power-sharing arrangement has led to a diminished focus on schools, fostering privatization. The study shows how upheavals in Lebanon have exacerbated educational challenges for families across all socioeconomic groups, leading to an increasing reliance on the unregulated shadow education sector, particularly private ...

The AGA Research Foundation awards $2.4 million in digestive health research funding

2025-04-22
Bethesda, MD (April 22, 2025) — The American Gastroenterological Association (AGA) is proud to announce the selection of 74 recipients to receive $2.4 million in research funding through the annual AGA Research Foundation Awards Program. AGA also announces today the addition of 10 pilot grants, totaling $400,000 in funding, to the 2026 awards portfolio to ensure that scientific discovery continues despite federal funding cuts. “Since we established the AGA Research Foundation in 1984, AGA has been unwavering in the commitment to supporting ...

A repurposed anti-inflammatory drug may help treat alcohol use disorder and related pain

2025-04-22
LA JOLLA, CA—A preclinical study from scientists at Scripps Research finds that a drug already FDA-approved for treating inflammatory conditions may help reduce both alcohol intake and pain sensitivity—two issues that commonly co-occur with alcohol use disorder (AUD). The results, published in JCI Insight on April 22, 2025, suggest that the drug apremilast—a phosphodiesterase-4 (PDE4) inhibitor, or a compound that blocks an enzyme involved in inflammation—could be repurposed as a dual-acting therapy for AUD, particularly in individuals who have pain during and after alcohol use. AUD ...

Obesity disrupts “reaction time” to starvation in mice

2025-04-22
Researchers led by Keigo Morita and Shinya Kuroda of the University of Tokyo have revealed a temporal disruption in the metabolism of obese mice when adapting to starvation despite no significant structural disruptions in the molecular network. This is a breakthrough discovery as research including the temporal dimension in biology has been notoriously laborious and extracting systematic insight from big data has been difficult. Thus, this study paves the way for further research into more general metabolic processes, such as food intake and disease progression. The findings were published in the journal Science Signaling. Living beings need to continuously extract energy from “food” ...

LAST 30 PRESS RELEASES:

Striking genomic architecture discovered in embryonic reproductive cells before they start developing into sperm and eggs

Screening improves early detection of colorectal cancer

New data on spontaneous coronary artery dissection (SCAD) – a common cause of heart attacks in younger women

How root growth is stimulated by nitrate: Researchers decipher signalling chain

Scientists reveal our best- and worst-case scenarios for a warming Antarctica

Cleaner fish show intelligence typical of mammals

AABNet and partners launch landmark guide on the conservation of African livestock genetic resources and sustainable breeding strategies

Produce hydrogen and oxygen simultaneously from a single atom! Achieve carbon neutrality with an 'All-in-one' single-atom water electrolysis catalyst

Sleep loss linked to higher atrial fibrillation risk in working-age adults

Visible light-driven deracemization of α-aryl ketones synergistically catalyzed by thiophenols and chiral phosphoric acid

Most AI bots lack basic safety disclosures, study finds

How competitive gaming on discord fosters social connections

CU Anschutz School of Medicine receives best ranking in NIH funding in 20 years

Mayo Clinic opens patient information office in Cayman Islands

Phonon lasers unlock ultrabroadband acoustic frequency combs

Babies with an increased likelihood of autism may struggle to settle into deep, restorative sleep, according to a new study from the University of East Anglia.

National Reactor Innovation Center opens Molten Salt Thermophysical Examination Capability at INL

International Progressive MS Alliance awards €6.9 million to three studies researching therapies to address common symptoms of progressive MS

Can your soil’s color predict its health?

Biochar nanomaterials could transform medicine, energy, and climate solutions

Turning waste into power: scientists convert discarded phone batteries and industrial lignin into high-performance sodium battery materials

PhD student maps mysterious upper atmosphere of Uranus for the first time

Idaho National Laboratory to accelerate nuclear energy deployment with NVIDIA AI through the Genesis Mission

Blood test could help guide treatment decisions in germ cell tumors

New ‘scimitar-crested’ Spinosaurus species discovered in the central Sahara

“Cyborg” pancreatic organoids can monitor the maturation of islet cells

Technique to extract concepts from AI models can help steer and monitor model outputs

Study clarifies the cancer genome in domestic cats

Crested Spinosaurus fossil was aquatic, but lived 1,000 kilometers from the Tethys Sea

MULTI-evolve: Rapid evolution of complex multi-mutant proteins

[Press-News.org] TOS statement on oral GLP-1s